Technology
Choose a subcategory:
Zecotek's continuous wave blue-green fiber lasers have been specifically developed as higher performance, lower cost replacements for argon ion and solid-state laser wavelengths in applications including: bio-instrumentation ( DNA sequencin
The corrected table follows: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Fiscal year ended March 31, Revenues: 2009 2008 Manufacturing $ 20,238,000 $ 24,402,000 Pharmaceutical $ 1,721,000 $ 232,000 Total revenues, net $ 21,959,000 $ 24,
Examples of such risks and uncertainties are: risks relating to the rigorous regulatory requirements required for approval of any drug or drug-device combination products that Discovery Labs may develop, including that: ( i) Discovery Labs
HARRISBURG, Pa., July 1, 2009 ( GLOBE NEWSWIRE)- Worldwide industrial services company Harsco Corporation today announced the following schedule and teleconference information for its second quarter 2009 earnings release.
Azixa ( tm), MPI's most advanced cancer drug candidate, which is currently in three Phase 2 clinical trials;* MPC-3100, a novel, fully-synthetic and orally-bioavailable heat shock protein 90 ( Hsp90) inhibitor and MPI's second clinical onco
Tel:+ 46 ( 0) 8? 661 0026 For pictures and press material, please contact: Alexandra Fleetwood, Director Communications Diamyd Medical AB ( publ.), alexandra. fleetwood@ diamyd. com Tel:+ 46 ( 0) 8 661 0026 About Diamyd Medical Diamyd Medic
STOCKHOLM, Sweden, July 1, 2009 ( GLOBE NEWSWIRE)- Quarterly report, March 1, 2009- May 31, 2009- The Swedish Medical Products Agency approved a study with the Diamyd ( r) vaccine for prevention of type 1 diabetes from manifesting in childr
About Rockwell Medical Technologies: Rockwell is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease ( ESRD), chronic kidney disease ( CKD), and iron deficiency
Dr. F. Tinney: Dr. Tinney spent his entire career working in the pharmaceutical industry with Parke-Davis, Warner Lambert and Pfizer Inc. Dr. Tinney earned his Ph. D. in organic chemistry from the University of Maryland and spent 20 years i
Chelsea Therapeutics Achieves Target Enrollment in Phase III Trial of Droxidopa in Neurogenic Orthos
Droxidopa, an orally active synthetic precursor of norepinephrine, increases the supply of norepinephrine available for delivery to its receptors to improve orthostatic blood pressure and alleviate symptoms of orthostatic hypotension.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Fiscal year ended March 31, 2009 2008 Total Revenues, net $ 20,238,000 $ 24,634,000 Gross Profit $ 2,904,000 $ 3,861,000 Stock compensation expense $ 1,461,000 $ 957,000 Depreciation and amort
Risks and uncertainties include whether external funding will be secured to support H1 DNA vaccine development; whether such vaccine will advance to clinical testing; whether results in animals will be predictive of results in humans; wheth